Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.58 |
| ▸ | DRD3 | P35462 | 5/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084725 | 1.00 | DRD2 (0.58) | DRD2DRD3KCNA3NPY5RHTR2A | |
| SCHEMBL4075309 | 0.89 | DRD2 (0.56) | DRD2DRD3KCNA3SIGMAR1 | |
| SCHEMBL4075310 | 0.89 | DRD2 (0.56) | DRD2DRD3KCNA3SIGMAR1 | |
| SCHEMBL4084310 | 0.86 | DRD2 (0.63) | DRD2DRD3KCNA3HTR2A | |
| SCHEMBL4084308 | 0.86 | DRD2 (0.63) | DRD2DRD3KCNA3HTR2A | |
| SCHEMBL3962394 | 0.79 | DRD2 (0.53) | DRD2DRD3KCNA3HTR2AHTR1A | |
| SCHEMBL3075416 | 0.79 | DRD2 (0.53) | DRD2DRD3KCNA3HTR2AHTR1A | |
| SCHEMBL3074452 | 0.78 | DRD2 (0.56) | DRD2DRD3KCNA3HTR2A | |
| SCHEMBL227037 | 0.78 | DRD2 (0.58) | DRD2DRD3KCNA3HTR2A | |
| SCHEMBL227036 | 0.78 | DRD2 (0.58) | DRD2DRD3KCNA3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438302-B1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2012-05-30 | — | — | EP | disclosed |
| US-7473692-B2 | Sulfonamide derivatives as D3-receptor ligands | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-06 | — | — | US | disclosed |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2005-05-19 | — | — | US | disclosed |
| EP-1438302-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003029233-A1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR AGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | SLC6A3, DRD3, GPR3 | DRD2 8/4885DRD3 2/4885KCNA3 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.